These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10086244)

  • 21. A more accurate measure of the false-negative rate of Papanicolaou smear screening is obtained by determining the false-negative rate of the rescreening process.
    Renshaw AA; DiNisco SA; Minter LJ; Cibas ES
    Cancer; 1997 Oct; 81(5):272-6. PubMed ID: 9349513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 100% rapid rescreening for quality assurance in a quality control program in a public health cytologic laboratory.
    Mattosinho de Castro Ferraz Mda G; Dall' Agnol M; di Loreto C; Pirani WM; Utagawa ML; Pereira SM; Sakai YI; Feres CL; Shih LW; Yamamoto LS; Rodrigues RO; Shirata NK; Longatta Filho A
    Acta Cytol; 2005; 49(6):639-43. PubMed ID: 16450904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection.
    Ronnett BM; Manos MM; Ransley JE; Fetterman BJ; Kinney WK; Hurley LB; Ngai JS; Kurman RJ; Sherman ME
    Hum Pathol; 1999 Jul; 30(7):816-25. PubMed ID: 10414501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NeoPath, Inc. NeoPath AutoPap 300 Automatic Pap Screener System.
    Patten SF; Lee JS; Nelson AC
    Acta Cytol; 1996; 40(1):45-52. PubMed ID: 8604574
    [No Abstract]   [Full Text] [Related]  

  • 25. AutoPap 300 QC system scoring of cervical smears without "epithelial cell abnormalities".
    Colgan TJ; Bon N; Lee JS; Patten SF
    Acta Cytol; 1997; 41(1):45-9. PubMed ID: 9022725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance of the AutoPap primary screening system at Jefferson University Hospital.
    Bibbo M; Hawthorne C
    Acta Cytol; 1999; 43(1):27-9. PubMed ID: 9987446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid prescreening as a quality assurance measure in cervical cytology.
    Repse-Fokter A; Caks-Golec T
    Acta Cytol; 2009; 53(3):268-70. PubMed ID: 19534265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for cervical disease in mature women: strategies for improvement.
    Colgan TJ; Clarke A; Hakh N; Seidenfeld A
    Cancer; 2002 Aug; 96(4):195-203. PubMed ID: 12209660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the PAPNET cytologic screening system for quality control of cervical smears.
    Koss LG; Lin E; Schreiber K; Elgert P; Mango L
    Am J Clin Pathol; 1994 Feb; 101(2):220-9. PubMed ID: 8116579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. False negatives in focused rescreening of Papanicolaou smears: how frequently are 'abnormal' cells detected in retrospective review of smears preceding cancer or high-grade intraepithelial neoplasia?
    Wilbur DC
    Arch Pathol Lab Med; 1997 Mar; 121(3):273-6. PubMed ID: 9111117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of false-negative Papanicolaou smears by rapid rescreening in a large routine cervical cytology laboratory.
    Wright RG; Halford JA; Ditchmen EJ
    Pathology; 1999 Nov; 31(4):379-81. PubMed ID: 10643010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of the MN antigen in cervical papanicolaou smears is an early diagnostic biomarker of cervical dysplasia.
    Liao SY; Stanbridge EJ
    Cancer Epidemiol Biomarkers Prev; 1996 Jul; 5(7):549-57. PubMed ID: 8827360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A feasibility study of the use of the AutoPap screening system as a primary screening and location-guided rescreening device.
    Confortini M; Bonardi L; Bulgaresi P; Cariaggi MP; Cecchini S; Ciatto S; Cipparrone I; Galanti L; Maddau C; Matucci M; Rubeca T; Troni GM; Turco P; Zappa M; Carozzi F
    Cancer; 2003 Jun; 99(3):129-34. PubMed ID: 12811852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the AutoPap (currently Focalpoint) primary screening system location guide use on interpretation time and diagnosis.
    Ronco G; Vineis C; Montanari G; Orlassino R; Parisio F; Arnaud S; Berardengo E; Fabbrini T; Segnan N
    Cancer; 2003 Apr; 99(2):83-8. PubMed ID: 12704687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computer-assisted rescreening of clinically important false negative cervical smears using the PAPNET Testing System.
    Rosenthal DL; Acosta D; Peters RK
    Acta Cytol; 1996; 40(1):120-6. PubMed ID: 8604564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pap smears with glandular cell abnormalities: Are they detected by rapid prescreening?
    Kanber Y; Charbonneau M; Auger M
    Cancer Cytopathol; 2015 Dec; 123(12):739-44. PubMed ID: 26348845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The primary screening clinical trials of the TriPath AutoPap System.
    Wilbur DC; Norton MK
    Epidemiology; 2002 May; 13 Suppl 3():S30-3. PubMed ID: 12071481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of false negative rates between 100% rapid review and 10% random full rescreening as internal quality control methods in cervical cytology screening.
    Lee BC; Lam SY; Walker T
    Acta Cytol; 2009; 53(3):271-6. PubMed ID: 19534266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can technology expedite the cervical cancer screening process? A Hong Kong experience using the AutoPap primary screening system with location-guided screening capability.
    Chang AR; Lin WF; Chang A; Chong KS
    Am J Clin Pathol; 2002 Mar; 117(3):437-43. PubMed ID: 11888083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Papanicolaou smear: can we make a good test better? Technical and interpretive challenges for the practitioner.
    Eltabbakh GH; Eltabbakh GD
    J Womens Health Gend Based Med; 1999 May; 8(4):469-76. PubMed ID: 10839701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.